A liquid pharmaceutical composition for use in the treatment of acute lymphoblastic leukaemia (ALL) comprising 6-mercaptopurine or a salt, hydrate or solvate thereof and a pharmaceutically-acceptable excipient, wherein the composition is a suspension for oral administration, a kit of parts for the accurate dosing and administration of the liquid pharmaceutical composition, and a method for the treatment of ALL in a human patient comprising administration of a therapeutically effective amount of ...

PURPOSE: A gold nanoparticle-purine complex is provided to show stability in cells or in vivo, to safely deliver a drug, and to release purine-based compounds at a desired time. CONSTITUTION: A gold nanoparticle-purine complex is provided. A purine compound is 6-mercaptopurine or 6-thioguanine. A drug delivery system has the gold nanoparticle-purine complex and glutathione. In the drug delivery system, the purine-based compounds are released from the gold nanoparticle-purine complex by treating ...

Methods of administering a delayed release 6-mercaptopurine pharmaceutical composition to patients suffering from inflammatory bowel disease which provide for release of the 6-mercaptopurine after passage of the pharmaceutical composition through the stomach are disclosed. The methods result in significant clinical improvement despite leading to very little systemic absorption of 6-mercaptopurine and also result in very few undesirable side effects.

Methods of administering a delayed release 6-mercaptopurine pharmaceutical composition to patients suffering from inflammatory bowel disease which provide for release of the 6-mercaptopurine after passage of the pharmaceutical composition through the stomach are disclosed. The methods result in significant clinical improvement despite leading to very little systemic absorption of 6-mercaptopurine and also result in very few undesirable side effects.

A liquid pharmaceutical composition for use in the treatment of acute lymphoblastic leukaemia (ALL) comprising 6-mercaptopurine or a salt, hydrate or solvate thereof and a pharmaceutically-acceptable excipient, wherein the composition is a suspension for oral administration, a kit of parts for the accurate dosing and administration of the liquid pharmaceutical composition, and a method for the treatment of ALL in a human patient comprising administration of a therapeutically effective amount of ...

A liquid pharmaceutical composition for use in the treatment of acute lymphoblastic leukaemia (ALL), comprising 6-mercaptopurine (6-MP) or a salt, hydrate or solvate thereof, wherein the composition is a suspension for oral administration. Preferably the composition is an aqueous oral dosage comprising 10-30 mg/mL (1.0-3.0% w/v) of 6-mercaptopurine monohydrate as suspended particles of diameter in the range of 3-85mm. The composition may be useful in particular as an oral paediatric formulation ...

The present invention provides improved formulations of 6-mercaptopurine that exhibit better bioavailability and faster dissolution than previous formulations.

The present invention provides improved formulations of 6-mercaptopurine that exhibit better bioavailability and faster dissolution than previous formulations.